CLOs on the Move

Regulatory Compliance Associates Inc

www.rcainc.biz

 
Regulatory Compliance Associates Inc is a Kenosha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.rcainc.biz
  • 7401 104th Ave
    Kenosha, WI USA 53142
  • Phone: 262.857.1250

Executives

Name Title Contact Details

Similar Companies

P.E.C.S.

P.E.C.S. is a Canovanas, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vero Biotech

Inhaled nitric oxide has the potential to benefit patients, with a range of cardiopulmonary conditions including COVID-19 Coronavirus.

Clearworth Systems

Clearworth Systems is a Rumson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Frontida BioPharm

Frontida BioPharm is a Minority-Owned Contract Development & Manufacturing Organization. We work collaboratively with our clients to bring new and improved products to the pharmaceutical market. By leveraging our team`s vast knowledge and experience we are able to improve the success of our client`s business and product development efforts. Frontida was launched by founding management team members of Frontage Laboratories. Having 15 years of success in the business Frontage remains a thriving CRO that has become a full service R&D organization located in PA, NJ, and China. With strong record of FDA compliance and quality service to global pharmaceutical and biotechnology companies, the Frontage team easily founded Frontida. While Frontage and Frontida remain affiliates, they are separate business entities.

Graybug Vision

Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.